



Iowa Department of Human Services

Kim Reynolds
Governor

Adam Gregg
Lt. Governor

Jerry R. Foxhoven
Director

Iowa Medicaid Drug Utilization Review (DUR) Commission Meeting

February 7, 2018

Location: Learning Resource Center
3550 Mills Civic Parkway
West Des Moines, Iowa, 50265
Fairmeadows Room

Time: 9:30 a.m. – 1:30 p.m.

Final Agenda

1. Welcome & Introductions
 - a) Commission Members and Staff
2. Commission Business
 - a) Approval of the Minutes
 - b) DHS Recommendation Letter – December 2017
3. IME Pharmacy Update
4. Fee-for-Service Program Prevalence Report Summary
5. MCO Prevalence Report Summary and Updates
 - a) Amerigroup
 - b) United Healthcare Community Plan
6. Public Comment* (See Conflict of Interest Disclosure Form)
7. ProDUR Edits
 - a) Quantity Limits
 - i. Antihypertensives – Initial Review
 - ii. Antiepileptics – Initial Review
 - b) Point of Sale Drug Utilization Review (DUR) Edits
 - i. Therapeutic Duplication
8. Prior Authorization
 - a) Deutetrabenazine (Austedo) & Valbenazine (Ingrezza) – Initial Review
 - b) CNS Stimulants and Atomoxetine – Initial Review
 - c) Anti-Diabetic Non-Insulin Agents - Initial Review

- d) Hepatitis C Treatments – Initial Review
- e) Buprenorphine/Naloxone – Second Review
- f) Smoking Cessation Therapy, Oral & Nicotine Replacement Therapy – Second Review
- g) Angiotensin Receptor Blocker Before ACE Inhibitor – Removal of Criteria – Second Review
- h) Immunomodulators, Topical – Second Review
- i) Ivacaftor (Kalydeco) – Second Review
- j) Lidocaine Patch – Second Review
- k) Topical Acne and Rosacea Products – Second Review

9. Miscellaneous

- a) DUR Digest Vol. 30, No. 2 – Second Review
- b) MedWatch
- c) Articles of Interest
 - i. Identifying the Most Prevalent and Costly Chronic Conditions in Medicaid
<http://www.ajmc.com/newsroom/identifying-the-most-prevalent-and-costly-chronic-conditions-in-medicaid>

10. Adjournment

*Individuals attending meetings of the DUR Commission shall have an opportunity to address the Commission. This opportunity will be granted once during the open portion of the meeting. In order to accommodate all interested parties, all speakers are requested to limit their comments to **5 minutes or less**. If you represent a drug manufacturer as an employee, as a contractor, as a member of the manufacturer's Speaker Bureau, or by any other means, we expect you to cover your individual product or entire product line in that five-minute time frame. Speakers who represent multiple manufacturers will share their 5 minutes with the other manufacturer representative(s) whose product they are speaking on.

www.iadur.org

For more information, contact the DUR Project Coordinator, Pamela Smith, R.Ph., at info@iadur.org or (515) 974-3131

*****Next Meeting April 4, 2018***
Location TBD**